Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid

Marei, HE; Althani, A; Caceci, T; Arriga, R; Sconocchia, T; Ottaviani, A; Lanzilli, G; Roselli, M; Caratelli, S; Cenciarelli, C; Sconocchia, G.
Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes.
BIOCHEM PHARMACOL. 2019; 166(9): 335-346.
Web of Science PubMed FullText FullText_MUG

 

Authors Med Uni Graz:
Sconocchia Tommaso
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
The chimeric antigen receptor T cell (CAR-T cell) immunotherapy currently represents a hot research trend and it is expected to revolutionize the field of cancer therapy. Promising outcomes have been achieved using CAR-T cell therapy for haematological malignancies. Despite encouraging results, several challenges still pose eminent hurdles before being fully recognized. Directing CAR-T cells to target a single tumour associated antigen (TAA) as the case in haematological malignancies might be much simpler than targeting the extensive inhibitory microenvironments associated with solid tumours. This review focuses on the basic principles involved in development of CAR-T cells, emphasizing the differences between humoral IgG, T-cell receptors, CAR and Fcγ-CR constructs. It also highlights the complex inhibitory network that is usually associated with solid tumours, and tackles recent advances in the clinical studies that have provided great hope for the future use of CAR-T cell immunotherapy. While current Fcγ-CR T cell immunotherapy is in pre-clinical stage, is expected to provide a sound therapeutic approach to add to existing classical chemo- and radio-therapeutic modalities. Copyright © 2019 Elsevier Inc. All rights reserved.

Find related publications in this database (Keywords)
Immunotherapy
CAR T cells
Fc gamma-CR T cell
Hematological malignancies
Solid cancers
© Med Uni GrazImprint